{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:32:27Z","timestamp":1786365147086,"version":"build-2736575974"},"reference-count":231,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZZYSM202311014"],"award-info":[{"award-number":["SZZYSM202311014"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.intimp.2024.112821","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T17:25:15Z","timestamp":1722446715000},"page":"112821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["MAFLD-related hepatocellular carcinoma: Exploring the potent combination of immunotherapy and molecular targeted therapy"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7246-147X","authenticated-orcid":false,"given":"Ziwei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.intimp.2024.112821_b0005","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2023.17935","article-title":"Diagnosis and management of nonalcoholic fatty liver disease","volume":"330","author":"Leung","year":"2023","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0015","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J. Hepatol."},{"issue":"10290","key":"10.1016\/j.intimp.2024.112821_b0020","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet (london, England)"},{"issue":"7","key":"10.1016\/j.intimp.2024.112821_b0025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112821_b0030","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0035","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112821_b0040","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41591-023-02602-2","article-title":"An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease","volume":"29","author":"Kendall","year":"2023","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0045","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0050","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41467-022-28138-6","article-title":"Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.intimp.2024.112821_b0055","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0060","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0065","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"8","key":"10.1016\/j.intimp.2024.112821_b0075","first-page":"1978","article-title":"The global burden of liver disease","volume":"21","author":"Younossi","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0080","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"9","key":"10.1016\/j.intimp.2024.112821_b0085","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0090","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"10","key":"10.1016\/j.intimp.2024.112821_b0095","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(\u2606)","volume":"73","author":"Anstee","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112821_b0110","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metab. Clin. Exp."},{"issue":"9","key":"10.1016\/j.intimp.2024.112821_b0115","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","article-title":"Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options","volume":"119","author":"Grander","year":"2023","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12916-017-0806-8","article-title":"Non-alcoholic fatty liver disease","volume":"15","author":"Neuschwander-Tetri","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.intimp.2024.112821_b0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.freeradbiomed.2019.05.029","article-title":"Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease","volume":"144","author":"Svegliati-Baroni","year":"2019","journal-title":"Free Rad. Biol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2024.112821_b0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0140","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0145","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jhep.2021.01.042","article-title":"FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease","volume":"75","author":"Liu","year":"2021","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0150","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12916-023-03028-w","article-title":"Plant-based diets, genetic predisposition and risk of non-alcoholic fatty liver disease","volume":"21","author":"Lv","year":"2023","journal-title":"BMC Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0160","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/hepr.13706","article-title":"MAFLD: Renovation of clinical practice and disease awareness of fatty liver","volume":"52","author":"Kawaguchi","year":"2022","journal-title":"Hepatol. Res.: Off. J. Jap. Soc. Hepatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112821_b0165","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int.: Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.intimp.2024.112821_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili","year":"2021","journal-title":"Mol. Metabol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b0175","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"7","key":"10.1016\/j.intimp.2024.112821_b0180","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112821_b0190","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2468-1253(22)00061-9","article-title":"Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the study of the liver and British society of gastroenterology NAFLD special interest group","volume":"7","author":"McPherson","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0195","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1097\/HEP.0000000000000586","article-title":"Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with \u201cLudwig disease\u201d","volume":"79","author":"Emanuele","year":"2024","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0200","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0205","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.jhep.2023.08.027","article-title":"Is the change from NAFLD to MASLD driven by political correctness?","volume":"80","author":"Sanal","year":"2024","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0210","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2024.112821_b0220","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0225","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b0230","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0235","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.112821_b0240","article-title":"Resmetirom: First Approval","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.112821_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122806","article-title":"Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions","volume":"351","author":"Somabattini","year":"2024","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0250","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: a review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0255","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular Carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10","key":"10.1016\/j.intimp.2024.112821_b0260","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0265","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/hep.32542","article-title":"NAFLD-related hepatocellular carcinoma: the growing challenge","volume":"77","author":"Shah","year":"2023","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"8","key":"10.1016\/j.intimp.2024.112821_b0270","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0275","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002\u20132033: the ITA.LI.CA database","volume":"72","author":"Vitale","year":"2023","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0280","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030516","article-title":"The current view of nonalcoholic fatty liver disease-related hepatocellular carcinoma","volume":"13","author":"Kogiso","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0290","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: a population-based cohort study","volume":"74","author":"Simon","year":"2021","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"8","key":"10.1016\/j.intimp.2024.112821_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/cells10082034","article-title":"NAFLD-related hepatocarcinoma: the malignant side of metabolic syndrome","volume":"10","author":"Michelotti","year":"2021","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.intimp.2024.112821_b0300","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102761","article-title":"Pathology and pathogenesis of metabolic dysfunction-associated steatotic liver disease-associated hepatic tumors","volume":"11","author":"Takahashi","year":"2023","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0305","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.112821_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102718","article-title":"The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers","volume":"125","author":"Starzer","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0315","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the liver\u2013from homeostasis to disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0320","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-0037-1604480","article-title":"Macrophages in nonalcoholic fatty liver disease: a role model of pathogenic immunometabolism","volume":"37","author":"Krenkel","year":"2017","journal-title":"Semin. Liver Dis."},{"issue":"51","key":"10.1016\/j.intimp.2024.112821_b0325","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba2351","article-title":"Immune surveillance of the liver by T cells","volume":"5","author":"Ficht","year":"2020","journal-title":"Sci. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0330","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/nu5051544","article-title":"Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease","volume":"5","author":"Gaggini","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.intimp.2024.112821_b0335","doi-asserted-by":"crossref","unstructured":"Li S, Brown MS, Goldstein JL: Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Nat. Acad. Sci. USA 2010, 107(8):3441-3446.","DOI":"10.1073\/pnas.0914798107"},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b0340","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.112821_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2021.111572","article-title":"Hepatic stellate cell senescence in liver fibrosis: characteristics, mechanisms and perspectives","volume":"199","author":"Zhang","year":"2021","journal-title":"Mech. Ageing Dev."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0350","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nm1166","article-title":"Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB","volume":"11","author":"Cai","year":"2005","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.intimp.2024.112821_b0355","doi-asserted-by":"crossref","first-page":"e115922","DOI":"10.1371\/journal.pone.0115922","article-title":"Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology","volume":"9","author":"Liang","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0360","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3701-1-14","article-title":"Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production","volume":"1","author":"Wang","year":"2011","journal-title":"Cell Biosci."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0365","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0370","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/labinvest.2012.45","article-title":"Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis","volume":"92","author":"Dixon","year":"2012","journal-title":"Lab. Invest.; J. Tech. Methods Pathol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0375","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2012.03.035","article-title":"Inflammasomes in liver diseases","volume":"57","author":"Szabo","year":"2012","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b0380","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061526","article-title":"Novel perspectives in immune checkpoint inhibitors and the management of non-alcoholic steatohepatitis-related hepatocellular carcinoma","volume":"14","author":"Chan","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0385","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052707","article-title":"PD-1\/PD-L1 immuno-mediated therapy in NAFLD: advantages and obstacles in the treatment of advanced disease","volume":"23","author":"Lombardi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0390","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1\u2013F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0395","first-page":"124","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.intimp.2024.112821_b0400","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp. Clin. Trials"},{"issue":"10019","key":"10.1016\/j.intimp.2024.112821_b0405","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet (london, England)"},{"issue":"10","key":"10.1016\/j.intimp.2024.112821_b0410","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0415","article-title":"Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis","volume":"3","author":"Bhattacharya","year":"2021","journal-title":"JHEP Rep. : Innov. Hepatol."},{"issue":"34","key":"10.1016\/j.intimp.2024.112821_b0420","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.3748\/wjg.v26.i34.5101","article-title":"Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation","volume":"26","author":"Fern\u00e1ndez-Ramos","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"10215","key":"10.1016\/j.intimp.2024.112821_b0425","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet (london, England)"},{"issue":"17","key":"10.1016\/j.intimp.2024.112821_b0430","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112821_b0435","article-title":"Advancements in pharmacological treatment of NAFLD\/MASLD: a focus on metabolic and liver-targeted interventions","volume":"12","author":"Ciardullo","year":"2024","journal-title":"Gastroenterol. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0440","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0445","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.intimp.2024.112821_b0450","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jor.2023.08.007","article-title":"Robotics and navigation in spine surgery: a narrative review","volume":"44","author":"Zawar","year":"2023","journal-title":"J. Orthop."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0455","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/liv.13031","article-title":"The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment","volume":"36","author":"Margini","year":"2016","journal-title":"Liver Int.: Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.intimp.2024.112821_b0460","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semcancer.2023.04.010","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: Insights in epidemiology, pathogenesis, imaging, prevention and therapy","volume":"93","author":"Polyzos","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0465","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-21-1258","article-title":"NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy","volume":"29","author":"Pinter","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.intimp.2024.112821_b0470","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147734","article-title":"Cell autophagy in NASH and NASH-related hepatocellular carcinoma","volume":"23","author":"Udoh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0475","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2020.10.030","article-title":"Hepatokines and adipokines in NASH-related hepatocellular carcinoma","volume":"74","author":"Kucukoglu","year":"2021","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0480","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.112821_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113869","article-title":"Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis","volume":"176","author":"Kumar","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2024.112821_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101833","article-title":"Emerging role of aging in the progression of NAFLD to HCC","volume":"84","author":"He","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0495","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0500","first-page":"935","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease","volume":"18","author":"Grimaudo","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"13","key":"10.1016\/j.intimp.2024.112821_b0505","first-page":"3314","article-title":"Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease","volume":"21","author":"Rosso","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"7","key":"10.1016\/j.intimp.2024.112821_b0510","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0515","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/cam4.4919","article-title":"CFDP1 promotes hepatocellular carcinoma progression through activating NEDD4\/PTEN\/PI3K\/AKT signaling pathway","volume":"12","author":"Zhou","year":"2023","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0520","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12964-020-00622-w","article-title":"Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma","volume":"18","author":"Zhao","year":"2020","journal-title":"Cell Commun. Signal"},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0525","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41419-024-06657-y","article-title":"Therapeutic role of PTEN in tissue regeneration for management of neurological disorders: stem cell behaviors to an in-depth review","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0530","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-021-00571-x","article-title":"PTEN suppresses tumorigenesis by directly dephosphorylating Akt","volume":"6","author":"Bu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0535","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.molcel.2019.08.006","article-title":"PTEN suppresses glycolysis by dephosphorylating and inhibiting autophosphorylated PGK1","volume":"76","author":"Qian","year":"2019","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.intimp.2024.112821_b0540","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/14728222.2019.1685501","article-title":"RAS\/RAF\/MEK\/ERK, PI3K\/PTEN\/AKT\/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma","volume":"23","author":"Akula","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b0545","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317705754","article-title":"PTEN: A potential prognostic marker in virus-induced hepatocellular carcinoma","volume":"39","author":"Khalid","year":"2017","journal-title":"Tumour Biol.: J. Int. Soc. Oncodevelop. Biol. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0550","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/cas.13177","article-title":"MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K\/Akt pathway","volume":"108","author":"Fu","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2024.112821_b0555","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-981-10-8684-7_5","article-title":"NAFLD related-HCC: the relationship with metabolic disorders","volume":"1061","author":"Zhang","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.intimp.2024.112821_b0560","doi-asserted-by":"crossref","unstructured":"T. Nguyen Huu, J. Park, Y. Zhang, H. Duong Thanh, I. Park, J.M. Choi, H.J. Yoon, S.C. Park, H.A. Woo, S.R. Lee, The Role of oxidative inactivation of phosphatase PTEN and TCPTP in fatty liver disease. Antioxidants (Basel, Switzerland) 2023, 12(1).","DOI":"10.3390\/antiox12010120"},{"issue":"44","key":"10.1016\/j.intimp.2024.112821_b0565","doi-asserted-by":"crossref","first-page":"E10417","DOI":"10.1073\/pnas.1808968115","article-title":"Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis","volume":"115","author":"Kodama","year":"2018","journal-title":"PNAS"},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0570","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050940","article-title":"MicroRNA-21 plays multiple oncometabolic roles in the process of NAFLD-related hepatocellular carcinoma via PI3K\/AKT, TGF-\u03b2, and STAT3 signaling","volume":"13","author":"Lai","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.intimp.2024.112821_b0575","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8080076","article-title":"Epigenetic activation of Wnt\/\u03b2-catenin signaling in NAFLD-associated hepatocarcinogenesis","volume":"8","author":"Tian","year":"2016","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0580","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.hbpd.2022.10.003","article-title":"Wnt\/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases","volume":"22","author":"Shree Harini","year":"2023","journal-title":"Hepatob. Pancr. Dis. Int.: HBPD INT"},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0585","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0590","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2019.08.016","article-title":"Gut microbiome in HCC - Mechanisms, diagnosis and therapy","volume":"72","author":"Schwabe","year":"2020","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0595","article-title":"Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature","volume":"20","author":"Milosevic","year":"2019","journal-title":"Int. J. Mole. Sci."},{"key":"10.1016\/j.intimp.2024.112821_b0600","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-med-090514-013832","article-title":"Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis","volume":"67","author":"Marengo","year":"2016","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0605","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/0008-5472.CAN-21-1020","article-title":"The protein kinase activity of NME7 activates Wnt\/\u03b2-catenin signaling to promote one-carbon metabolism in hepatocellular carcinoma","volume":"82","author":"Ren","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0610","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b0615","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","article-title":"N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells' properties and lenvatinib resistance through WNT\/\u03b2-catenin and hippo signaling pathways","volume":"164","author":"Wang","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0620","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0625","doi-asserted-by":"crossref","DOI":"10.3390\/genes15020197","article-title":"Franzoso G: NF-\u03baB: governing macrophages in cancer","volume":"15","author":"Cornice","year":"2024","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0630","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.it.2022.11.005","article-title":"NF-\u03baB dynamics in the language of immune cells","volume":"44","author":"Aqdas","year":"2023","journal-title":"Trends Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112821_b0635","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1002\/jcp.30759","article-title":"NF-\u03baB as a regulator of cancer metastasis and therapy response: A focus on epithelial-mesenchymal transition","volume":"237","author":"Mirzaei","year":"2022","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0640","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","article-title":"NF-\u03baB, inflammation, immunity and cancer: coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112821_b0645","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-\u03baB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2024.112821_b0650","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-\u03baB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0655","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s13238-013-2084-3","article-title":"NF-\u03baB and STAT3 signaling pathways collaboratively link inflammation to cancer","volume":"4","author":"Fan","year":"2013","journal-title":"Protein Cell"},{"issue":"9","key":"10.1016\/j.intimp.2024.112821_b0660","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.it.2022.07.004","article-title":"NF-\u03baB: blending metabolism, immunity, and inflammation","volume":"43","author":"Capece","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2024.112821_b0665","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584626","article-title":"Regulation of PD-L1 Expression by NF-\u03baB in Cancer","volume":"11","author":"Antonangeli","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0670","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/tox.23851","article-title":"Scoparone inhibits the development of hepatocellular carcinoma by modulating the p38 MAPK\/Akt\/NF-\u03baB signaling in nonalcoholic fatty liver disease mice","volume":"39","author":"Ye","year":"2024","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.intimp.2024.112821_b0675","doi-asserted-by":"crossref","unstructured":"J.C. Arroyave-Ospina, Z. Wu, Y. Geng, H. Moshage, Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy. Antioxidants (Basel, Switzerland) 2021, 10(2).","DOI":"10.3390\/antiox10020174"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0680","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1038\/s41467-022-33493-5","article-title":"Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK","volume":"13","author":"Ge","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2024.112821_b0685","article-title":"Relevance of SIRT1-NF-\u039ab Axis as therapeutic target to ameliorate inflammation in liver disease","volume":"21","author":"de Gregorio","year":"2020","journal-title":"Int. Jo. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0690","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2024.112821_b0695","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1111\/jcmm.17228","article-title":"JAK-STAT core cancer pathway: An integrative cancer interactome analysis","volume":"26","author":"Erdogan","year":"2022","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0700","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b0705","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0710","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/path.6065","article-title":"TUBB4B is a novel therapeutic target in non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"260","author":"Yang","year":"2023","journal-title":"J. Pathol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112821_b0715","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/17474124.2020.1802244","article-title":"Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"14","author":"Anastasopoulos","year":"2020","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112821_b0720","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41580-023-00591-1","article-title":"Cellular and molecular mechanisms of Hedgehog signalling","volume":"24","author":"Zhang","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0725","doi-asserted-by":"crossref","first-page":"e13162","DOI":"10.1111\/cpr.13162","article-title":"Research progress on the hedgehog signalling pathway in regulating bone formation and homeostasis","volume":"55","author":"Zhou","year":"2022","journal-title":"Cell Prolif."},{"issue":"7","key":"10.1016\/j.intimp.2024.112821_b0730","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrm3598","article-title":"The mechanisms of Hedgehog signalling and its roles in development and disease","volume":"14","author":"Briscoe","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112821_b0735","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0740","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/10409238.2018.1448752","article-title":"The hedgehog pathway in nonalcoholic fatty liver disease","volume":"53","author":"Verdelho Machado","year":"2018","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0745","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jhep.2017.06.008","article-title":"Human germline hedgehog pathway mutations predispose to fatty liver","volume":"67","author":"Guillen-Sacoto","year":"2017","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0750","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-021-01435-2","article-title":"Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling","volume":"20","author":"Gu","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2024.112821_b0755","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.acr.2020.10.002","article-title":"Signaling pathways in hepatocellular carcinoma","volume":"149","author":"Garcia-Lezana","year":"2021","journal-title":"Adv. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0760","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/hep.28381","article-title":"HEDGEHOG Signal in hepatocytes mediates macrophage recruitment: a new mechanism and potential therapeutic target for fatty liver disease","volume":"63","author":"Seki","year":"2016","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0765","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/hep.28289","article-title":"Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease","volume":"63","author":"Kwon","year":"2016","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"12","key":"10.1016\/j.intimp.2024.112821_b0770","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00109-014-1223-5","article-title":"p53 in liver pathologies-taking the good with the bad","volume":"92","author":"Charni","year":"2014","journal-title":"J. Mol. Med. (Berl)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0775","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1038\/s41467-023-41852-z","article-title":"URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers","volume":"14","author":"Ding","year":"2023","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.intimp.2024.112821_b0780","doi-asserted-by":"crossref","first-page":"9168","DOI":"10.1111\/jcmm.16792","article-title":"P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization","volume":"25","author":"You","year":"2021","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0785","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/cvr\/cvu118","article-title":"P53 inhibition exacerbates late-stage anthracycline cardiotoxicity","volume":"103","author":"Zhu","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0790","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jhep.2020.05.028","article-title":"Peptide SMIM30 promotes HCC development by inducing SRC\/YES1 membrane anchoring and MAPK pathway activation","volume":"73","author":"Pang","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.112821_b0795","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev-pathol-030420-105050","article-title":"The Hippo Pathway in Liver Homeostasis and Pathophysiology","volume":"16","author":"Driskill","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b0800","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nrgastro.2016.59","article-title":"The Hippo pathway in intestinal regeneration and disease","volume":"13","author":"Hong","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0805","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41575-021-00571-w","article-title":"Hippo signalling in the liver: role in development, regeneration and disease","volume":"19","author":"Russell","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b0810","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/cas.15352","article-title":"Physiological and pathological roles of the Hippo-YAP\/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis","volume":"113","author":"Nishina","year":"2022","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0815","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jhep.2021.09.032","article-title":"Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis","volume":"76","author":"Qing","year":"2022","journal-title":"J. Hepatol."},{"issue":"19","key":"10.1016\/j.intimp.2024.112821_b0820","doi-asserted-by":"crossref","first-page":"17495","DOI":"10.1007\/s00432-023-05473-9","article-title":"Components of the JNK-MAPK pathway play distinct roles in hepatocellular carcinoma","volume":"149","author":"Yu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0825","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00109-022-02179-2","article-title":"c-Met up-regulates the expression of PD-L1 through MAPK\/NF-\u03baBp65 pathway","volume":"100","author":"Xu","year":"2022","journal-title":"J. Mol. Med. (Berl)"},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0830","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.gendis.2020.05.004","article-title":"Regulation of ferroptosis in cancer cells by YAP\/TAZ and Hippo pathways: the therapeutic implications","volume":"8","author":"Sun","year":"2021","journal-title":"Genes Dis."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b0835","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/21541248.2018.1435986","article-title":"Reciprocal regulation of YAP\/TAZ by the Hippo pathway and the Small GTPase pathway","volume":"11","author":"Jang","year":"2020","journal-title":"Small GTPases"},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0840","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0845","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","article-title":"Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma","volume":"79","author":"Li","year":"2024","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0850","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/HEP.0000000000000386","article-title":"Therapeutic modulation of the liver immune microenvironment","volume":"78","author":"Tilg","year":"2023","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.intimp.2024.112821_b0855","doi-asserted-by":"crossref","first-page":"1225821","DOI":"10.3389\/fphar.2023.1225821","article-title":"The effect of liver disease on hepatic microenvironment and implications for immune therapy","volume":"14","author":"Brown","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0860","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jhep.2022.03.015","article-title":"Unique molecular characteristics of NAFLD-associated liver cancer accentuate \u03b2-catenin\/TNFRSF19-mediated immune evasion","volume":"77","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0865","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0870","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1038\/s41467-021-27574-0","article-title":"Depletion of central memory CD8(+) T cells might impede the antitumor therapeutic effect of Mogamulizumab","volume":"12","author":"Maeda","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.112821_b0875","article-title":"Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy","volume":"11","author":"Jiang","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0880","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000438631","article-title":"Hepatocellular carcinoma cells induce regulatory T cells and lead to poor prognosis via production of transforming growth factor-\u03b21","volume":"38","author":"Wang","year":"2016","journal-title":"Cell. Physiol. Biochem.: Int. J. Exp. Cellul. Physiol., Biochem., Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0885","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejso.2007.08.008","article-title":"Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma","volume":"34","author":"Sasaki","year":"2008","journal-title":"Eur. J. Surg. Oncol.: J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0890","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jhep.2006.01.036","article-title":"Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma","volume":"45","author":"Yang","year":"2006","journal-title":"J. Hepatol."},{"issue":"22","key":"10.1016\/j.intimp.2024.112821_b0895","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212190","article-title":"T cell subsets and natural killer cells in the pathogenesis of nonalcoholic fatty liver disease","volume":"22","author":"Gebru","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.112821_b0900","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fimmu.2017.00301","article-title":"Immunoregulatory role of NK cells in tissue inflammation and regeneration","volume":"8","author":"Tosello-Trampont","year":"2017","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112821_b0905","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41423-022-00872-3","article-title":"Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver","volume":"19","author":"Tang","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"7854","key":"10.1016\/j.intimp.2024.112821_b0910","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0915","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112821_b0920","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0925","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","article-title":"NAFLD-driven HCC: safety and efficacy of current and emerging treatment options","volume":"76","author":"Foerster","year":"2022","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112821_b0930","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2019.05.014","article-title":"Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis","volume":"71","author":"Yau","year":"2019","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0935","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112821_b0940","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0945","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"},{"issue":"7854","key":"10.1016\/j.intimp.2024.112821_b0950","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0955","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0960","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.apsb.2022.10.021","article-title":"A metabolic intervention strategy to break evolutionary adaptability of tumor for reinforced immunotherapy","volume":"13","author":"Feng","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b0965","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41577-019-0140-9","article-title":"Metabolic interventions in the immune response to cancer","volume":"19","author":"O'Sullivan","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112821_b0970","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112821_b0975","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cmet.2022.01.001","article-title":"New avenues for NASH therapy by targeting ACC","volume":"34","author":"Bian","year":"2022","journal-title":"Cell Metab."},{"issue":"12","key":"10.1016\/j.intimp.2024.112821_b0980","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0985","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/s12916-023-03185-y","article-title":"Genetically predicted plasma levels of amino acids and metabolic dysfunction-associated fatty liver disease risk: a Mendelian randomization study","volume":"21","author":"Zhao","year":"2023","journal-title":"BMC Med."},{"issue":"23","key":"10.1016\/j.intimp.2024.112821_b0990","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1016\/j.cell.2023.09.011","article-title":"Arginine reprograms metabolism in liver cancer via RBM39","volume":"186","author":"Mossmann","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b0995","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b1000","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-019-0742-5","article-title":"Immune cell therapy for hepatocellular carcinoma","volume":"12","author":"Mizukoshi","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b1005","doi-asserted-by":"crossref","first-page":"e13413","DOI":"10.1111\/obr.13413","article-title":"Using adipose-derived mesenchymal stem cells to fight the metabolic complications of obesity: Where do we stand?","volume":"23","author":"Mik\u0142osz","year":"2022","journal-title":"Obes. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b1010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s13287-020-01951-w","article-title":"Application of human amniotic epithelial cells in regenerative medicine: a systematic review","volume":"11","author":"Zhang","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.intimp.2024.112821_b1015","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/768071","article-title":"The role of dendritic cells in fibrosis progression in nonalcoholic fatty liver disease","volume":"2015","author":"Almeda-Valdes","year":"2015","journal-title":"Biomed Res. Int."},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b1020","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jhep.2017.02.018","article-title":"Liver dendritic cells and NAFLD evolution: a remaining open issue","volume":"66","author":"Bernsmeier","year":"2017","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b1025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","article-title":"Dendritic cells in cancer immunology","volume":"19","author":"Murphy","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2024.112821_b1030","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162322","article-title":"Supercharged chimeric antigen receptor T cells in solid tumors","volume":"132","author":"Pant","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b1035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/imr.12794","article-title":"Immunobiology of chimeric antigen receptor T cells and novel designs","volume":"290","author":"Walsh","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2024.112821_b1040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.984864","article-title":"Chimeric antigen receptor T cells applied to solid tumors","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"issue":"25","key":"10.1016\/j.intimp.2024.112821_b1045","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3748\/wjg.v25.i25.3136","article-title":"Hepatocellular carcinoma: therapeutic advances in signaling, epigenetic and immune targets","volume":"25","author":"Neureiter","year":"2019","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b1050","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b1055","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jceh.2022.07.003","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"12","author":"Roy","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.intimp.2024.112821_b1060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.655697","article-title":"Hepatocellular carcinoma immune landscape and the potential of immunotherapies","volume":"12","author":"Giraud","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112821_b1065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112821_b1070","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b1075","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.intimp.2024.112821_b1080","article-title":"METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.112821_b1085","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","article-title":"MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1","volume":"156","author":"Li","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.112821_b1090","doi-asserted-by":"crossref","unstructured":"A. Santoro, E. Assenat, T. Yau, J.P. Delord, M. Maur, J. Knox, S. Cattan, K.H. Lee, G. Del Conte, C. Springfeld et al: A phase Ib\/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma. JHEP reports : innovation in hepatology 2024, 6(4):101021.","DOI":"10.1016\/j.jhepr.2024.101021"},{"issue":"12","key":"10.1016\/j.intimp.2024.112821_b1095","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/2159-8290.CD-19-0367","article-title":"Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma","volume":"9","author":"Hatlen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2024.112821_b1100","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c00758","article-title":"Discovery of 2,6-naphthyridine analogues as selective FGFR4 inhibitors for hepatocellular carcinoma","author":"Oh","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2024.112821_b1105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41419-024-06625-6","article-title":"Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression","volume":"15","author":"Cui","year":"2024","journal-title":"Cell Death Dis."},{"issue":"10408","key":"10.1016\/j.intimp.2024.112821_b1110","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet (london, England)"},{"issue":"12","key":"10.1016\/j.intimp.2024.112821_b1115","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2024.112821_b1120","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ (clinical Research Ed)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b1125","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2020.01.004","article-title":"Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: many unresolved issues","volume":"73","author":"Choudhary","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2024.112821_b1130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.991052","article-title":"Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"28","key":"10.1016\/j.intimp.2024.112821_b1135","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.3748\/wjg.v28.i28.3595","article-title":"Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?","volume":"28","author":"Mattos","year":"2022","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b1140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-024-01527-8","article-title":"Metabolic reprogramming in the tumor microenvironment of liver cancer","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112821_b1145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12935-023-03019-0","article-title":"Glycolysis-related biomarker TCIRG1 participates in regulation of renal cell carcinoma progression and tumor immune microenvironment by affecting aerobic glycolysis and AKT\/mTOR signaling pathway","volume":"23","author":"Di","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2024.112821_b1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121503","article-title":"ATP-exhausted nanocomplexes for intratumoral metabolic intervention and photoimmunotherapy","volume":"284","author":"Yu","year":"2022","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.intimp.2024.112821_b1155","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163291","article-title":"Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models","volume":"133","author":"Lu","year":"2023","journal-title":"J. Clin. Invest."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924013420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924013420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:06:01Z","timestamp":1786363561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924013420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":231,"alternative-id":["S1567576924013420"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112821","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MAFLD-related hepatocellular carcinoma: Exploring the potent combination of immunotherapy and molecular targeted therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112821"}}